<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446976</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P13 1.9</org_study_id>
    <secondary_id>135134</secondary_id>
    <nct_id>NCT03446976</nct_id>
  </id_info>
  <brief_title>CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Open-label, Single-dose, Two-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of the Pre-filled Syringe and Auto-injector of CT-P13 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares two administration methods of CT-P13. Half of participants will receive
      CT-P13 by pre-filled syringe while the other half will receive CT-P13 by auto-injector.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I Study to Compare Pharmacokinetics and Safety between CT-P13 SC Pre-filled
      Syringe and CT-P13 SC Auto-injector in Healthy Subjects. A total of 218 healthy subjects will
      be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Actual">July 26, 2018</completion_date>
  <primary_completion_date type="Actual">July 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate comparable pharmacokinetics (PK) of CT-P13 subcutaneous (SC) administered by auto-injector (AI) versus pre-filled syringe (PFS) in healhty subjects.</measure>
    <time_frame>over 12 weeks</time_frame>
    <description>Pharmacokinetics will be assessed by AUC</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Health, Subjective</condition>
  <arm_group>
    <arm_group_label>CT-P13 SC Auto-injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-P13 SC Auto-injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-P13 SC Pre-filled Syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-P13 SC Pre-filled Syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P13 SC Auto-injector</intervention_name>
    <description>Each subject may receive single dose by subcutaneous administration using Auto-Injector</description>
    <arm_group_label>CT-P13 SC Auto-injector</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P13 SC Pre-filled Syringe</intervention_name>
    <description>Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe</description>
    <arm_group_label>CT-P13 SC Pre-filled Syringe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subject

          -  Subject voluntarily agrees to participate in this study

        Exclusion Criteria:

          -  Subject with medical history and/or condition

          -  Female who is pregnant or breastfeeding, or childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SuEun Song</last_name>
    <role>Study Chair</role>
    <affiliation>Celltrion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

